Abstract: What is disclosed is a method for isolating the cold insoluble globulin (CIG) from blood plasma concentrates containing factor VIII.

Abstract: A solid fibrinogen formulation is described, which formulation contains, in addition to fibrinogen, a substance containing the urea or guanidine radical, and a process for its preparation. This formulation is used for the preparation of a fibrinogen solution which is suitable as an adhesive for human and animal tissue and as a fibrinogen concentrate for intravenous administration.

Abstract: A process for the preparation of a pasteurized human citrated plasma is described, in which citrated plasma, from which the prothrombin factors and labile proteins have been removed, is heated in the presence of stabilizers.

Abstract: A process for the pasteurization of antihemophilic cryoprecipitate (AHC) is described, wherein AHC is heated in the presence of calicum ions, an amino acid and a carbohydrate. The pasteurized AHC is used for the treatment of coagulation disturbances.

Abstract: What is disclosed is a process for rendering plasminogen virtually free of hepatitis virus by heating a plasminogen solution in the presence of a proteinase inhibitor with plasmin specificity, an amino acid, and a saccharide or sugar alcohol.

Abstract: A process for purifying liquids containing blood clotting factors by adsorption of the factors on mineral adsorbents such as calcium phosphate, aluminum hydroxide gel, barium sulfate or hydroxylapatite in the presence of calcium ions followed by elution is described.

Abstract: What is disclosed is a method for making a preparation containing blood clotting Factors IX and/or X virtually hepatitis-safe by warming said peparation in the presence of calcium ions and in the further presence of an amino acid and/or a saccharide or sugar alcohol.

Abstract: What is disclosed is a method for treating a preparation containing blood clotting Factors II and/or VII to render it virtually hepatitis-free by warming said preparation in the presence of a chelating agent and in the further presence of an amino acid and/or a saccharide or sugar alcohol.

Abstract: Process for the manufacture of a collagen solution and its use for the manufacture of collagen fibrillae for adsorbing coagulation factors, as diagnostic agent, for the manufacture of a collagen sponge and for use in a cosmetic preparation.

Abstract: Process for the manufacture of a collagen solution and its use for the manufacture of collagen fibrillae for adsorbing coagulation factors, as diagnostic agent, for the manufacture of a collagen sponge and for use in a cosmetic preparation.

Abstract: What is disclosed is a process for isolating or purifying the third component of complement (C 3) from blood plasma and other solutions containing C 3 using a material with affinity for C 3 such as protamine or a salt thereof, which is fixed to a carrier.

Abstract: A process for stabilizing the coagulation factors II, VIII, XIII, antithrombin III and plasminogen against heat is described. The preparations obtained according to this process are practically free from coagulable fibrinogen.

Abstract: A homogeneous suspension, in a buffered aqueous solution having a pH of 7.0 to 7.7, of a destroyed microorganism which is positive to the clumping factor, said suspension containing from 3 to 50 percent by weight of at least one polyhydric alcohol soluble therein, is disclosed, as are its manufacture and its use as a reagent for the determination of fibrinogen and for fibrin cleavage products.

Abstract: What is disclosed is a plastics material adaptable to biomedical uses, the surface of which material at least partially consists of a graft copolymer having a hydrocarbon main chain and side chains grafted thereon, said side chains being polymers comprising at least one vinyl monomer selected from the group consisting of acrylic acid esters of the formulaCF.sub.3 --(CF.sub.2).sub.x --(CH.sub.2).sub.y --O--CO--CH.dbd.CH.sub.2,where x is an integer from 3 to 16 and y is an integer from 1 to 12, vinylene carbonate, N-vinyl alkylamides of the formula ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and each is hydrogen or alkyl having 1 to 6 carbon atoms.

Abstract: A method for the treatment of thromboembolisms in a patient, said method consisting essentially of intravenously administering to said patient an effective amount of a complex formed between streptokinase and plasminogen in a mol ratio from 2:1 to 1:2 in combination with a physiologically tolerable aqueous liquid diluent.

Abstract: Antithrombin III in plasma or serum is determined by combining diluted plasma or serum with heparin or heparinoids and thrombin to form a mixture, permitting the mixture to stand, thereafter adding to the mixture a fibrinogen solution and determining the coagulation time. The heparin or heparinoids and thrombin can be combined together to form a reagent for use in the determination.

Abstract: The invention relates to an antihemophilic agent, which may contain factor VIII, but also factor IV, VII and X activities and to a process for its manufacture by extracting placentae with an aqueous hypotonic medium, increasing the density of the extract and obtaining the supernatant layer forming thereupon.

Abstract: Lyophilized blood plasma under a protective gas wherein the protective gas contains at least 5% of carbon dioxide.

Abstract: The invention relates to a process for the analytical determination of human plasminogen which comprises mixing a liquid containing diluted human plasminogen withA. a catalyst, such as streptokinase, converting human plasminogen into human plasminogen activator,B. fibrinogen andC. a plasminogen, such as the plasminogen of a ruminant, e.g. bovine plasminogen, which cannot be activated by the catalyst andD. thrombinAnd determining the coagulation of the mixture.